Article
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Nature - 1 May 2021
Collier Dami A, De Marco Anna, Ferreira Isabella A T M, Meng Bo, Datir Rawlings P, Walls Alexandra C, Kemp Steven A, Bassi Jessica, Pinto Dora, Silacci-Fregni Chiara, Bianchi Siro, Tortorici M Alejandra, Bowen John, Culap Katja, Jaconi Stefano, Cameroni Elisabetta, Snell Gyorgy, Pizzuto Matteo S, Pellanda Alessandra Franzetti, Garzoni Christian, Riva Agostino, Elmer Anne, Kingston Nathalie, Graves Barbara, McCoy Laura E, Smith Kenneth G C, Bradley John R, Temperton Nigel, Ceron-Gutierrez Lourdes, Barcenas-Morales Gabriela, Harvey William, Virgin Herbert W, Lanzavecchia Antonio, Piccoli Luca, Doffinger Rainer, Wills Mark, Veesler David, Corti Davide, Gupta Ravindra K
Abstract excerpt
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant1, which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune...
Topics
Join the communities discussing this publication.